Sentence examples for core registry from inspiring English sources

Patients who do not qualify for CERTAIN based upon disease activity criteria or the enrollment ratio are recruited to the CORRONA "core" registry.

Unlike in CERTAIN, the CORRONA core registry does not mandate specific laboratory values, and thus the labs collected by the CORRONA registry reflect what is felt to be appropriate by the treating rheumatologist in the course of routine clinical care.

Once collected, these core registry data are then combined with additional CIHI data from both the Hospital Morbidity Database ("HMDB", which contains national data on hospital inpatient events) and the Discharge Abstract Database ("DAD", which contains national data on hospital discharges) to produce both the yearly reports and "analysis in brief" reports.

However, further data explorations are required to examine infection- and population-specific outcomes within the EU-CORE registry in detail.

Real-world data from the EU-CORE registry study suggest that daptomycin is effective and well tolerated in patients with neutropenia and Gram-positive infections.

Among the 446 patients with neutropenia from the EU-CORE registry who received daptomycin, there was a high clinical success rate (77.1%).

A total of 6,075 patients were enrolled in the EU-CORE registry, of whom 638 (10.5 %) had osteomyelitis (non-prosthetic and prosthetic device-related) and orthopaedic device infections.

The data from the EU-CORE registry illustrate 8 years of clinical experience of real-world usage of daptomycin against a variety of Gram-positive infections including drug-resistant pathogens (MRSA, CoNS, and VRE) in patients with multiple co-morbidities.

Of the 6075 patients enrolled in EU-CORE registry who had received at least one dose of daptomycin, 446 (7.3%) had an ANC ≤1000 cells/mm at baseline or during daptomycin treatment; 50% (n = 223) had severe neutropenia (ANC ≤100 cells/mm).

The objective of the present analysis was to evaluate the effectiveness and safety of daptomycin in a lager cohort of patients with primary infections of osteomyelitis, non-prosthetic and prosthetic device-related, or orthopaedic device infections, enrolled in the EU-CORE registry and followed for up to 2 years after the end of daptomycin therapy.

We ranked a "core clinical registry" as less costly than an "extended clinical registry" because the data items that define an "extended clinical registry" are more difficult and time-consuming to collect and therefore more costly.